Onglyza (saxagliptin) is a DPP-4 inhibitor approved for treatment of type 2-diabetes in combination with metformin, sulfonylurea, or glitazones. The dose is 5 mg (1 tablet) a day.
Compared with placebo, saxagliptin shows a significant reduction of both HbA1c and fasting plasma glucose levels. The percentage of patients reaching an HbA1c < 7 %, is also larger for treatment with saxagliptin than for placebo treatment. Saxagliptin is non-inferior to sitagliptin regarding reduction of HbA1c.
No results on clinically relevant outcomes , such as micro- or macrovascular complications and mortality have been published.
The long-term effects are, at present, unknown.
The short-term side effects are mild and on a placebo level. Long-term side effects are still unknown.
The price for a year of treatment with Onglyza 5mg/day is 5,354 D.kr. Onglyza is under the rules of general reimbursement.
IRF finds that Onglyza can be considered for patients who are intolerant of metformin or sulfonylurea, and who are not sufficiently glycaemically controlled on monotherapy.